United Therapeutics (UTHR) Stock Forecast: StockMap's 2-Week Call
UTHR stock forecast: StockMap's model makes no two-week call on United Therapeutics after the Nov 13 close: its evidence is split, 9 reasons for and 6 against. Too few two-week windows graded to judge yet.
United Therapeutics last closed at $591.17, -0.36% on the session.
Against the IVW growth benchmark the position is +0.55% over the forecast window.
United Therapeutics' market cap is $25.18B as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 18 (too close to call).
Where UTHR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 9 bullish and 6 bearish.
Agreement across those insights is 60%.
6 daily calls for UTHR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks United Therapeutics in the 41st percentile on valuation and the 79th percentile on return on equity, where 100 is best.
United Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks United Therapeutics as the 15th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite United Therapeutics ranks 21st of 391 in the group, against a group median of -0.24.